SavedAdd your journal

Journals / İzmir Göğüs Hastanesi Dergisi / 2021 / Cilt: 35 - Sayı: 1

Assessment of Serum Endocan and sICAM-1 Levels as Markers of Endothelial Dysfunction and Systemic Inflammation and Their Relationship with Comorbidities in COPD Patients

KOAH Hastalarında Endotel Disfonksiyonu ve Sistemik İnflamasyon Belirteçleri Olarak Serum Endokan ve sICAM-1 Düzeylerinin Değerlendirilmesi ve Bunların Komorbiditelerle Olan İlişkisi

Fisun Karadağ
Şule Taş Gülen
Onur Yazıcı
Burcu Talay Mustafaoğlu
Aslıhan Büyüköztürk Karul
Pages
1–10
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Serum endocan and soluble ICAM-1 (sICAM-1) levels were measuredby the ELISA method.Results: Endocan and sICAM-1 levels of the COPD group were higher (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Chronic obstructive pulmonary disease (COPD) has systemic effects and is accompanied by numerous comorbidities.
📊
Key Findings & Data:Systemic inflammation and endothelial dysfunction increase the incidence of comorbidities in COPD.
💡
Conclusion & Impact:Serum endocan and soluble ICAM-1 (sICAM-1) levels were measuredby the ELISA method.Results: Endocan and sICAM-1 levels of the COPD group were higher (p
🔬Design:Survey & Empirical Study
📍Scope:2018 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: Chronic obstructive pulmonary disease (COPD) has systemic effects and is accompanied by numerous comorbidities. Systemic inflammation and endothelial dysfunction increase the incidence of comorbidities in COPD. Endocan andIntercellular Adhesion Molecule-1 (ICAM-1) can be used as indicators for determining endothelial dysfunction and systemic inflammation. We aimed to investigate endothelial dysfunction and systemic inflammation using endocan andsICAM-1 levels and determine associations of these indicators with comorbidities in COPD patients.Method: COPD patients who presented to Outpatient Chest Diseases Clinic between May 2018 and May 2019 and acontrol group were included in the study. Demographic data, comorbidities, forced vital capacity (FVC)%, forced expiratoryvolume in 1-second (FEV1)%, and FEV1/FVC, Modified Medical Research Council (mMRC) dyspnea scores, and COPDassessment-questionnaire (CAT) scores of COPD patients were recorded. COPD patients were divided into two groups asthose with/without comorbidities. Besides, they were classified into four groups (A-D) according to the GOLD (GlobalInitiative for Obstructive Lung Disease) classification. Serum endocan and soluble ICAM-1 (sICAM-1) levels were measuredby the ELISA method.Results: Endocan and sICAM-1 levels of the COPD group were higher (p

Özet

Amaç: Kronik obstrüktif akciğer hastalığı (KOAH) birçok komorbiditenin eşlik ettiği ve sistemik etkileri olan bir hastalıktır. Sistemik inflamasyon ve endotel disfonksiyonu KOAH’da komorbidite görülme sıklığını arttırmaktadır. Endokan ve hücreler arası adezyon molekülü 1(ICAM-1) endotel disfonksiyonu ve sistemik inflamasyonu belirlemede belirteç olarak kullanılabilir. Biz de çalışmamızda, KOAH hastalarında endokan ve ICAM-1 düzeyi ile endotel disfonksiyonu ve sistemik inflamasyonu değerlendirmeyi ve komorbiditelerin bu belirteçlerle olan ilişkisini değerlendirmeyi amaçladık. Yöntem: Çalışmamıza Mayıs 2018-Mayıs 2019 tarihleri arasında Göğüs Hastalıkları Polikliniğine başvuran KOAH hastaları ve kontrol grubu alındı. Tüm olguların demografik verileri, komorbiditeleri, zorlu vital kapasite (FVC) %, zorlu ekspiratuvar volüm birinci saniye (FEV1) % ve FEV1/FVC parametreleri ve Modified Medical Research Council (mMRC) dispne skalası skorları ile KOAH olgularının KOAH değerlendirme anketi (CAT) skorları kaydedildi. KOAH hastaları komorbiditesi olan ve olmayanlar olarak 2 gruba ayrıldı. KOAH hastaları ayrıca GOLD sınıflamasına göre A’dan D’ye 4 gruba ayrıldı. Endokan ve soluble ICAM-1 (sICAM-1) düzeyleri serumda ELISA yöntemiyle ölçüldü. Bulgular: KOAH grubunda endokan ve sICAM-1 değerleri daha yüksekti (p değerleri sırasıyla

🔖

Cite This Article

Karadağ, F., Gülen, Ş. T., Yazıcı, O., Mustafaoğlu, B. T., Karul, A. B. (2022). Assessment of Serum Endocan and sICAM-1 Levels as Markers of Endothelial Dysfunction and Systemic Inflammation and Their Relationship with Comorbidities in COPD Patients. İzmir Göğüs Hastanesi Dergisi, Cilt: 35 - Sayı: 1, 1–10. https://ajindex.com/articles/557813

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017. Available from:
  2. Okutan O, Ayten Ö. Kronik obstrüktif akciğer hastalığı ve komorbiditeler. Solunum 2012;14(3):182-3.
  3. Kechagia M, Papassotiriou I, Gourgoulianis KI. Endocan and the respiratory system: a review. Int J Chron Obstruct Pulmon Dis. 2016;11:3179-87.
  4. Arnson Y, Shoenfeld Y, Amital H. Effects of tobacco smoke on immunity inflammation and autoimmunity. J Autoimmun 2010;34:258-65.
  5. Hillas G, Perlikos F, Tsiligianni I, Tzanakis N. Managing comorbidites in COPD. Int J Chron Obstruct Pulmon Dis 2015;10:95-109.
  6. Dursunoğlu N, Köktürk N, Baha A, et al. Turkish Thoracic Society-COPD Comorbidity Group. Comorbities and their impact on chronic obstructive pulmonary disease. Tuberk Toraks 2016;64:292-301.
  7. Béchard D, Scherpereel A, Hammad H, et al. Human endothelial-cell specific molecule-1 binds directly to the integrin CD11a/CD18 (LFA-1) and blocks binding to intercellular adhesion molecule-1. J Immunol 2001;167(6):3099-106.
  8. Mikkelsen ME, Shah CV, Scherpereel A, et al. Lower serum endocan levels are associated with the development of acute lung injury after major trauma. J Crit Care 2012;27(5):522.
  9. Tang L, Zhao Y, Wang D, et al. Endocan levels in peripheral blood predict outcomes of acute respiratory distress syndrome. Mediators Inflamm 2014;2014:625180.
  10. Grigoriu BD, Depontieu F, Scherpereel A, et al. Endocan expression and relationship with survival in human nonsmall cell lung cancer. Clin Cancer Res 2006;12(15):4575- 82.
  11. Kao SJ, Chuang CY, Tang CH, et al. Plasma endothelial cell-specific molecule-1 (ESM-1) in management of community-acquired pneumonia. Clin Chem Lab Med. 2014;52(3):445-51.
  12. Güzel A, Duran L, Köksal N, et al. Evaluation of serum endothelial cell specific molecule-1 (endocan) levels as a biomarker in patients with pulmonary thromboembolism. Blood Coagul Fibrinolysis 2014;25(3):272-6.
  13. Kechagia M, Michalakakou K, Gr